Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

3(60.0%)

Phase 1

1(20.0%)

Phase 4

1(20.0%)

5Total

Phase 3(3)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07464340Phase 1Completed

Rivastigmine Transdermal Patches Bioequivalence and Adhesion Assessment

Role: lead

NCT05304169Phase 4Completed

Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.

Role: lead

NCT02448199Phase 3Unknown

Study of Association of Anti-inflammatory and Anti-rheumatic

Role: lead

NCT00838487Phase 3Unknown

Evaluate Safety & Efficacy of Condroflex in Subjects With OA

Role: lead

NCT00889356Phase 3Unknown

Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis

Role: lead

All 5 trials loaded